Mutated processes predict immune checkpoint inhibitor therapy benefit in metastatic melanoma
Abstract Immune Checkpoint Inhibitor (ICI) therapy has revolutionized treatment for advanced melanoma; however, only a subset of patients benefit from this treatment. Despite considerable efforts, the Tumor Mutation Burden (TMB) is the only FDA-approved biomarker in melanoma. However, the mechanisms...
Main Authors: | Andrew Patterson, Noam Auslander |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2022-09-01
|
Series: | Nature Communications |
Online Access: | https://doi.org/10.1038/s41467-022-32838-4 |
Similar Items
-
Author Correction: Mutated processes predict immune checkpoint inhibitor therapy benefit in metastatic melanoma
by: Andrew Patterson, et al.
Published: (2023-09-01) -
Machine Learning Improves the Prediction of Responses to Immune Checkpoint Inhibitors in Metastatic Melanoma
by: Azadeh Tabari, et al.
Published: (2023-05-01) -
Plasma glycoproteomic biomarkers identify metastatic melanoma patients with reduced clinical benefit from immune checkpoint inhibitor therapy
by: Chad Pickering, et al.
Published: (2023-06-01) -
Cardiovascular Immunotoxicity Associated with Immune Checkpoint Inhibitors in Metastatic Melanoma
by: Jean-Matthieu L’Orphelin, et al.
Published: (2023-04-01) -
Immune checkpoint inhibitors for metastatic uveal melanoma: a meta-analysis
by: Kayoko Yamada, et al.
Published: (2024-04-01)